

Mads Agerbaek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9059434/publications.pdf>

Version: 2024-02-01

52
papers

2,385
citations

331259

21
h-index

233125

45
g-index

54
all docs

54
docs citations

54
times ranked

3307
citing authors

#	ARTICLE	IF	CITATIONS
1	Can whole-body MRI replace CT in management of metastatic testicular cancer? A prospective, non-inferiority study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1221-1230.	1.2	4
2	Cognitive impairment and associations with structural brain networks, endocrine status, and risk genotypes in newly orchiectomized testicular cancer patients. <i>Brain Imaging and Behavior</i> , 2022, 16, 199-210.	1.1	5
3	Immune Contexture and Differentiation Features Predict Outcome in Bladder Cancer. <i>European Urology Oncology</i> , 2022, 5, 203-213.	2.6	14
4	Implications for Efficacy and Safety of Total Dose and Dose-Intensity of Neoadjuvant Gemcitabine-Cisplatin in Muscle-Invasive Bladder Cancer: Three-Week Versus Four-Week Regimen. <i>Bladder Cancer</i> , 2022, 8, 71-80.	0.2	4
5	Long-term neurotoxicity and quality of life in testicular cancer survivors—a nationwide cohort study. <i>Journal of Cancer Survivorship</i> , 2021, 15, 509-517.	1.5	15
6	Adverse health behaviours in long-term testicular cancer survivors: a Danish nationwide study. <i>Acta Oncologica</i> , 2021, 60, 361-369.	0.8	4
7	Genome-wide circulating tumor DNA monitoring for bladder cancer treatment management and organ preservation.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16527-e16527.	0.8	0
8	Cognitive changes and brain connectomes, endocrine status, and risk genotypes in testicular cancer patients—A prospective controlled study. <i>Cancer Medicine</i> , 2021, 10, 6249-6260.	1.3	3
9	Reply to: Reconciling differences in impact of molecular subtyping on response to cisplatin-based chemotherapy. <i>Nature Communications</i> , 2021, 12, 4834.	5.8	3
10	Treatment and Survival in Advanced Non-Small Cell Lung Cancer, Urothelial, Ovarian, Gastric and Kidney Cancer: A Nationwide Comprehensive Evaluation. <i>Clinical Epidemiology</i> , 2021, Volume 13, 871-882.	1.5	1
11	Sexual Function and Quality of Life in a National Cohort of Survivors of Bilateral Testicular Cancer. <i>European Urology Focus</i> , 2020, 6, 711-719.	1.6	9
12	Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM). <i>European Journal of Cancer</i> , 2020, 127, 173-182.	1.3	16
13	Cardiovascular Risk Factors and Disease After Male Germ Cell Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 584-592.	0.8	52
14	Psychological stress in long-term testicular cancer survivors: a Danish nationwide cohort study. <i>Journal of Cancer Survivorship</i> , 2020, 14, 72-79.	1.5	12
15	Ten years of experience with MRI follow-up of testicular cancer stage I: a retrospective study and an MRI protocol with DWI. <i>Acta Oncologica</i> , 2020, 59, 1374-1381.	0.8	8
16	Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis. <i>Nature Communications</i> , 2020, 11, 4858.	5.8	124
17	GCT-65. INCIDENCE AND OUTCOME OF INTRACRANIAL MALIGNANT GERM CELL TUMOURS DIAGNOSED IN WESTERN DENMARK IN THE LAST DECADE. <i>Neuro-Oncology</i> , 2020, 22, iii341-iii341.	0.6	0
18	Safety and Activity of Sorafenib in Addition to Vinflunine in Post-Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial. <i>Oncologist</i> , 2019, 24, 745-e213.	1.9	7

#	ARTICLE	IF	CITATIONS
19	Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1547-1557.	0.8	298
20	Abstract 913: Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. , 2019, , .		3
21	Optimized targeted sequencing of cell-free plasma DNA from bladder cancer patients. <i>Scientific Reports</i> , 2018, 8, 1917.	1.6	50
22	Limited post-chemotherapy retroperitoneal resection of residual tumour in non-seminomatous testicular cancer: complications, outcome and quality of life. <i>Acta OncolÃ³gica</i> , 2018, 57, 1084-1093.	0.8	11
23	Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis. <i>European Urology</i> , 2018, 73, 535-540.	0.9	112
24	Cohort Profile: The Danish Testicular Cancer Late Treatment Effects Cohort (DaTeCa-LATE). <i>Frontiers in Oncology</i> , 2018, 8, 37.	1.3	13
25	Sexual Function in a Nationwide Cohort of 2,260 Survivors of Testicular Cancer after 17 Years of Followup. <i>Journal of Urology</i> , 2018, 200, 794-800.	0.2	22
26	Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer. <i>European Urology</i> , 2017, 71, 961-969.	0.9	154
27	Surveillance versus adjuvant radiotherapy for patients with highâ€™risk stage I seminoma. <i>Cancer</i> , 2017, 123, 1212-1218.	2.0	36
28	Changes in Brain Structural Networks and Cognitive Functions in Testicular Cancer Patients Receiving Cisplatin-Based Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	66
29	Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study. <i>European Urology</i> , 2017, 71, 290-298.	0.9	59
30	Changes in cognitive functions and cerebral grey matter and their associations with inflammatory markers, endocrine markers, and APOE genotypes in testicular cancer patients undergoing treatment. <i>Brain Imaging and Behavior</i> , 2017, 11, 769-783.	1.1	65
31	The Danish Testicular Cancer database. <i>Clinical Epidemiology</i> , 2016, Volume 8, 703-707.	1.5	21
32	Second Malignant Neoplasms and Cause of Death in Patients With Germ Cell Cancer. <i>JAMA Oncology</i> , 2016, 2, 1624.	3.4	77
33	Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer. <i>European Urology</i> , 2016, 70, 75-82.	0.9	174
34	Late Relapses in Stage I Testicular Cancer Patients on Surveillance. <i>European Urology</i> , 2016, 70, 365-371.	0.9	34
35	Reply to C. Rusner et al, L.C. Pagliaro et al, and K. Lu. <i>Journal of Clinical Oncology</i> , 2015, 33, 2326-2327.	0.8	0
36	Surgery After Relapse in Stage I Nonseminomatous Testicular Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2322-2322.	0.8	6

#	ARTICLE	IF	CITATIONS
37	Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3â€”pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 76-86.	5.1	323
38	Intra-fractional bladder motion and margins in adaptive radiotherapy for urinary bladder cancer. <i>Acta OncolÃ³gica</i> , 2015, 54, 1461-1466.	0.8	26
39	Cognitive impairment and potential biological and psychological correlates of neuropsychological performance in recently orchiectomized testicular cancer patients. <i>Psycho-Oncology</i> , 2015, 24, 1174-1180.	1.0	34
40	Germ Cell Cancer and Multiple Relapses: Toxicity and Survival. <i>Journal of Clinical Oncology</i> , 2015, 33, 3116-3123.	0.8	29
41	Germ cell cancer and multiple relapses: Toxicity and survival.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4533-4533.	0.8	0
42	A Nationwide Cohort Study of Stage I Seminoma Patients Followed on a Surveillance Program. <i>European Urology</i> , 2014, 66, 1172-1178.	0.9	151
43	Surveillance for Stage I Nonseminoma Testicular Cancer: Outcomes and Long-Term Follow-Up in a Population-Based Cohort. <i>Journal of Clinical Oncology</i> , 2014, 32, 3817-3823.	0.8	189
44	No effect of pirfenidone treatment in fulminant bleomycin-induced pneumonitis. <i>Respiratory Medicine Case Reports</i> , 2014, 12, 47-49.	0.2	2
45	Final results of EORTC intergroup randomized phase III trial comparing immediate versus deferred chemotherapy after radical cystectomy in patients with pT3T4 and/or N+ M0 transitional cell carcinoma (TCC) of the bladder.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4500-4500.	0.8	9
46	Renal impairment and late toxicity in germ-cell cancer (GCC) survivors.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4555-4555.	0.8	0
47	Screening for carcinoma in situ (CIS) testis and occurrence of metachronous germ cell cancer (mGCC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4554-4554.	0.8	0
48	A nationwide cohort study of surveillance for stage I seminoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4502-4502.	0.8	9
49	Germ cell cancer (GCC): Long-term survival after treatment with bleomycin (B), etoposide (E), and cisplatin (P) in a large cohort.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4533-4533.	0.8	4
50	Phase I results from a study of lapatinib with gemcitabine and cisplatin (GC) in advanced/metastatic bladder cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 252-252.	0.8	7
51	Expression of TIP60 (tatâ€”interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatmentâ€”specific outcome of localised invasive bladder cancer. <i>BJU International</i> , 2012, 110, E1228-36.	1.3	92
52	Focal S100A4 Protein Expression Is an Independent Predictor of Development of Metastatic Disease in Cystectomized Bladder Cancer Patients. <i>European Urology</i> , 2006, 50, 777-785.	0.9	26